Factory Mutual Insurance Co. Makes New Investment in Fresenius Medical Care AG & Co. KGaA $FMS

Factory Mutual Insurance Co. acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 67,196 shares of the company’s stock, valued at approximately $1,769,000.

A number of other institutional investors also recently modified their holdings of FMS. Todd Asset Management LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 5.2% in the 3rd quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock valued at $34,319,000 after buying an additional 64,311 shares in the last quarter. ABC Arbitrage SA grew its stake in Fresenius Medical Care AG & Co. KGaA by 18.2% in the second quarter. ABC Arbitrage SA now owns 229,375 shares of the company’s stock valued at $6,553,000 after acquiring an additional 35,314 shares during the period. Envestnet Asset Management Inc. grew its stake in Fresenius Medical Care AG & Co. KGaA by 26.8% in the second quarter. Envestnet Asset Management Inc. now owns 373,961 shares of the company’s stock valued at $10,684,000 after acquiring an additional 78,956 shares during the period. Pzena Investment Management LLC increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% during the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock valued at $390,128,000 after acquiring an additional 153,870 shares in the last quarter. Finally, Trustmark Bank Trust Department acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter worth approximately $1,027,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on FMS. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Erste Group Bank lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Weiss Ratings downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. The Goldman Sachs Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Finally, Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Five equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS stock opened at $24.11 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.36 and a quick ratio of 1.00. The firm has a 50-day moving average of $23.31 and a 200-day moving average of $24.47. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.94 and a one year high of $30.46. The company has a market cap of $13.98 billion, a P/E ratio of 17.60, a P/E/G ratio of 0.76 and a beta of 0.90.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.